trending Market Intelligence /marketintelligence/en/news-insights/trending/aAzpJvn2x3KOesgChhGqrw2 content esgSubNav
In This List

Achillion drug secures second US FDA orphan drug designation

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Achillion drug secures second US FDA orphan drug designation

Achillion Pharmaceuticals Inc. secured the U.S. Food and Drug Administration's orphan drug designation for ACH-4471 to treat a rare, kidney-related disease known as C3 Glomerulopathy.

ACH-4471 previously received the U.S. FDA's orphan drug designation to treat paroxysmal nocturnal hemoglobinuria that is characterized by red blood cell destruction, blood clots and impaired bone marrow function.